|
1
|
Endo-Munoz L, Evdokiou A and Saunders NA:
The role of osteoclasts and tumour-associated macrophages in
osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442.
2012.PubMed/NCBI
|
|
2
|
Poletajew S, Fus L and Wasiutynski A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.(In
English, Polish). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis VO: What's new in musculoskeletal
oncology. J Bone Joint Surg Am. 91:1546–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho Y, Jung GH, Chung SH, Kim JY, Choi Y
and Kim JD: Long-term survivals of stage IIb osteosarcoma: A
20-year experience in a single institution. Clin Orthop Surg.
3:48–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bölling T, Schüller P, Distelmaier B,
Schuck A, Ernst I, Gosheger G, Winkelmann W, Dirksen U, Jürgens H,
Kronholz HL, et al: Perioperative high-dose rate brachytherapy
using a bendy applicator (flab): Treatment results of 74 patients.
Anticancer Res. 28:3885–3890. 2008.PubMed/NCBI
|
|
6
|
Faisham WI, Saad Mat AZ, Alsaigh LN, Azman
Nor MZ, Imran Kamarul M, Biswal BM, Bhavaraju VM, Salzihan MS,
Hasnan J, Ezane AM, et al: Prognostic factors and survival rate of
osteosarcoma: A single-institution study. Asia Pac J Clin Oncol.
13:e104–e110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bacci G, Bertoni F, Longhi A, Ferrari S,
Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G, et
al: Neoadjuvant chemotherapy for high-grade central osteosarcoma of
the extremity. Histologic response to preoperative chemotherapy
correlates with histologic subtype of the tumor. Cancer.
97:3068–3075. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
11
|
Farh KK, Grimson A, Jan C, Lewis BP,
Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact
of mammalian MicroRNAs on mRNA repression and evolution. Science.
310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pasquinelli AE, Hunter S and Bracht J:
MicroRNAs: Adeveloping story. Curr Opin Genet Dev. 15:200–205.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin S, Pan L, Guo S, Wu J, Jin L, Wang JC
and Wang S: Prognostic role of microRNA-181a/b in hematological
malignancies: A meta-analysis. PLoS One. 8:e595322013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meng Y, Gao R, Ma J, Zhao J, Xu E, Wang C
and Zhou X: MicroRNA-140-5p regulates osteosarcoma chemoresistance
by targeting HMGN5 and autophagy. Sci Rep. 7:4162017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vanas V, Haigl B, Stockhammer V and
Sutterlüty-Fall H: MicroRNA-21 increases proliferation and
cisplatin sensitivity of osteosarcoma-derived cells. PLoS One.
11:e01610232016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Zhu ST, Wang X, Deng J, Li WH,
Zhang P and Liu BS: MiR-200c regulates tumor growth and
chemosensitivity to cisplatin in osteosarcoma by targeting AKT2.
Sci Rep. 7:135982017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song
JS, Tang LH, Levine AJ and Feng Z: Negative regulation of tumor
suppressor p53 by microRNA miR-504. Mol Cell. 38:689–699. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bedi A and Mookerjee B: Biological
significance and molecular mechanisms of p53-induced apoptosis.
Apoptosis. 3:237–244. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Velletri T, Xie N, Wang Y, Huang Y, Yang
Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, et al: P53 functional
abnormality in mesenchymal stem cells promotes osteosarcoma
development. Cell Death Dis. 7:e20152016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z
and Huang Y: Histone deacetylase inhibitor sodium butyrate
suppresses proliferation and promotes apoptosis in osteosarcoma
cells by regulation of the MDM2-p53 signaling. Onco Targets Ther.
9:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao YX, Wang YS, Cai QQ, Wang JQ and Yao
WT: Up-regulation of HDAC9 promotes cell proliferation through
suppressing p53 transcription in osteosarcoma. Int J Clin Exp Med.
8:11818–11823. 2015.PubMed/NCBI
|
|
25
|
Wu J, Guo A, Li Q and Wang D:
Meta-analysis of clinical significance of p53 protein expression in
patients with osteosarcoma. Future Oncol. 13:1883–1891. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van der Deen M, Taipaleenmäki H, Zhang Y,
Teplyuk NM, Gupta A, Cinghu S, Shogren K, Maran A, Yaszemski MJ,
Ling L, et al: MicroRNA-34c inversely couples the biological
functions of the runt-related transcription factor RUNX2 and the
tumor suppressor p53 in osteosarcoma. J Biol Chem. 288:21307–21319.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang J, Ma B, Li X, Jin W, Han C, Wang L
and Wang H: MiR-1281, a p53-responsive MicroRNA, impairs the
survival of human osteosarcoma cells upon ER stress via targeting
USP39. Am J Cancer Res. 8:1764–1774. 2018.PubMed/NCBI
|
|
28
|
He C, Xiong J, Xu X, Lu W, Liu L, Xiao D
and Wang D: Functional elucidation of MiR-34 in osteosarcoma cells
and primary tumor samples. Biochem Biophys Res Commun. 388:35–40.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang W, Qian JX, Yi HL, Yang ZD, Wang CF,
Chen JY, Wei XZ, Fu Q and Ma H: The microRNA-29 plays a central
role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk).
46:622–627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai Q, Zeng S, Dai X, Wu J and Ma W:
miR-504 promotes tumour hrowth and metastasis in human osteosarcoma
by targeting TP53INP1. Oncol Rep. 38:2993–3000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lv C, Hao Y and Tu G: MicroRNA-21 promotes
proliferation, invasion and suppresses apoptosis in human
osteosarcoma line MG63 through PTEN/Akt pathway. Tumour Biol.
37:9333–9342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui R, Guan Y, Sun C, Bao Y, Chen L, Li G,
Qiu B, Meng X, Pang C and Wang Y: A tumor-suppressive microRNA,
miR-504, inhibits cell proliferation and promotes apoptosis by
targeting FOXP1 in human Glioma. Cancer Lett. 374:1–11. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015.doi: 10.7554/eLife.05005. View Article : Google Scholar
|
|
35
|
Stepanenko AA and Dmitrenko VV: HEK293 in
cell biology and cancer research: Phenotype, karyotype,
tumorigenicity, and stress-induced genome-phenotype evolution.
Gene. 569:182–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nieuwenhuijsen BW, Huang Y, Wang Y,
Ramirez F, Kalgaonkar G and Young KH: A dual luciferase multiplexed
high-throughput screening platform for protein-protein
interactions. J Biomol Screen. 8:676–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rosen G, Caparros B, Huvos AG, Kosloff C,
Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B and Urban C:
Preoperative chemotherapy for osteogenic sarcoma: Selection of
postoperative adjuvant chemotherapy based on the response of the
primary tumor to preoperative chemotherapy. Cancer. 49:1221–1230.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bennett JH, Thomas G, Evans AW and Speight
PM: Osteosarcoma of the jaws: A 30-year retrospective review. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod. 90:323–332. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang L, Shrestha S, LaChaud G, Scott MA
and James AW: Review of microRNA in osteosarcoma and
chondrosarcoma. Med Oncol. 32:6132015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kumar Ram RM, Boro A and Fuchs B:
Involvement and clinical aspects of MicroRNA in osteosarcoma. Int J
Mol Sci. 17:pii: E877. 2016.
|
|
41
|
Kobayashi E, Hornicek FJ and Duan Z:
MicroRNA involvement in osteosarcoma. Sarcoma. 2012:3597392012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang J, Guo W, Wang L, Yu L, Mei H, Fang
S, Ji P, Liu Y, Liu G and Song Q: Cisplatin-resistant osteosarcoma
cells possess cancer stem cell properties in a mouse model. Oncol
Lett. 12:2599–2605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song L, Duan P, Gan Y, Li P, Zhao C, Xu J,
Zhang Z and Zhou Q: Silencing LPAATβ inhibits tumor growth of
cisplatin-resistant human osteosarcoma in vivo and in
vitro. Int J Oncol. 50:535–544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim M, Jung JY, Choi S, Lee H, Morales LD,
Koh JT, Kim SH, Choi YD, Choi C, Slaga TJ, et al: GFRA1 promotes
cisplatin-induced chemoresistance in osteosarcoma by inducing
autophagy. Autophagy. 13:149–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng D, Wu W, Dong N, Jiang X, Xu J, Zhan
X, Zhang Z and Hu Z: Mxd1 mediates hypoxia-induced cisplatin
resistance in osteosarcoma cells by repression of the PTEN tumor
suppressor gene. Mol Carcinog. 56:2234–2244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zou Y, Yang J, Wu J, Luo C and Huang Y:
miR-133b induces chemoresistance of osteosarcoma cells to cisplatin
treatment by promoting cell death, migration and invasion. Oncol
Lett. 15:1097–1102. 2018.PubMed/NCBI
|
|
47
|
Ziyan W and Yang L: MicroRNA-21 regulates
the sensitivity to cisplatin in a human osteosarcoma cell line. Ir
J Med Sci. 185:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song YD, Li DD, Guan Y, Wang YL and Zheng
J: miR-214 modulates cisplatin sensitivity of osteosarcoma cells
through regulation of anaerobic glycolysis. Cell Mol Biol
(Noisy-le-grand). 63:75–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang F, Yu D, Liu Z, Wang R, Xu Y, Cui H
and Zhao T: MiR-125b functions as a tumor suppressor and enhances
chemosensitivity to cisplatin in osteosarcoma. Technol Cancer Res
Treat. 15:NP105–NP112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Y, Jiang W, Hu Y, Da Z, Zeng C, Tu M,
Deng Z and Xiao W: MicroRNA-199a-5p inhibits cisplatin-induced drug
resistance via inhibition of autophagy in osteosarcoma cells. Oncol
Lett. 12:4203–4208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yang MH, Lin BR, Chang CH, Chen ST, Lin
SK, Kuo MY, Jeng YM, Kuo ML and Chang CC: Connective tissue growth
factor modulates oral squamous cell carcinoma invasion by
activating a miR-504/FOXP1 signalling. Oncogene. 31:2401–2411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jiang B, Gu Y and Chen Y: Identification
of novel predictive markers for the prognosis of pancreatic ductal
adenocarcinoma. Cancer Invest. 32:218–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Soutto M, Chen Z, Saleh MA, Katsha A, Zhu
S, Zaika A, Belkhiri A and El-Rifai W: TFF1 activates p53 through
down-regulation of miR-504 in gastric cancer. Oncotarget.
5:5663–5673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kikkawa N, Kinoshita T, Nohata N, Hanazawa
T, Yamamoto N, Fukumoto I, Chiyomaru T, Enokida H, Nakagawa M,
Okamoto Y and Seki N: microRNA-504 inhibits cancer cell
proliferation via targeting CDK6 in hypopharyngeal squamous cell
carcinoma. Int J Oncol. 44:2085–2092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guan Y, Chen L, Bao Y, Pang C, Cui R, Li
G, Liu J and Wang Y: Downregulation of microRNA-504 is associated
with poor prognosis in high-grade glioma. Int J Clin Exp Pathol.
8:727–734. 2015.PubMed/NCBI
|
|
57
|
Mirzayans R, Andrais B, Kumar P and Murray
D: Significance of wild-type p53 signaling in suppressing apoptosis
in response to chemical genotoxic agents: Impact on chemotherapy
outcome. Int J Mol Sci. 18:pii: E928. 2017.
|
|
58
|
Vassilev LT, Vu BT, Graves B, Carvajal D,
Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et
al: In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hu W, Feng Z, Ma L, Wagner J, Rice JJ,
Stolovitzky G and Levine AJ: A single nucleotide polymorphism in
the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in
cells. Cancer Res. 67:2757–2765. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hansen MF: Molecular genetic
considerations in osteosarcoma. Clin Orthop Relat Res. 237–246.
1991.PubMed/NCBI
|
|
61
|
Hauben EI, Arends J, Vandenbroucke JP, van
Asperen CJ, Van Marck E and Hogendoorn PC: Multiple primary
malignancies in osteosarcoma patients. Incidence and predictive
value of osteosarcoma subtype for cancer syndromes related with
osteosarcoma. Eur J Hum Genet. 11:611–618. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ford NA, Dunlap SM, Wheatley KE and
Hursting SD: Obesity, independent of p53 gene dosage, promotes
mammary tumor progression and upregulates the p53 regulator
microRNA-504. PLoS One. 8:e680892013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fukuda Y, Kurihara N, Imoto I, Yasui K,
Yoshida M, Yanagihara K, Park JG, Nakamura Y and Inazawa J: CD44 is
a potential target of amplification within the 11p13 amplicon
detected in gastric cancer cell lines. Genes Chromosomes Cancer.
29:315–324. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Novello C, Pazzaglia L, Conti A, Quattrini
I, Pollino S, Perego P, Picci P and Benassi MS: p53-dependent
activation of microRNA-34a in response to etoposide-induced DNA
damage in osteosarcoma cell lines not impaired by dominant negative
p53 expression. PLoS One. 9:e1147572014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Braun CJ, Zhang X, Savelyeva I, Wolff S,
Moll UM, Schepeler T, Ørntoft TF, Andersen CL and Dobbelstein M:
p53-responsive micrornas 192 and 215 are capable of inducing cell
cycle arrest. Cancer Res. 68:10094–10104. 2008. View Article : Google Scholar : PubMed/NCBI
|
